LT3001 DEMONSTRATES FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DISABLING ACUTE ISCHEMIC STROKE

Lumosa Therapeutics Co., Ltd. Taiwan

Breakthrough Phase 2 Trial Results Show Promise for Patients Ineligible for Standard Reperfusion TherapiesData Presented at International Stroke ConferenceData Show That LT3001 Delivers Meaningful Functional Improvements in Patients Suffering from Disabling Acute Ischemic Stroke (AIS)View original content:https://www.prnewswire.co.uk/news-releases/lt3001-demonstrates-functional-improvements-in-patients-with-disabling-acute-ischemic-stroke-302681220.html